Loading financials from SEC filings…
Biotechnology · Healthcare · Fiscal year ends Dec 31
Net income was −$131M. Operating cash flow of −$112M less capital expenditure of $794,000 left free cash flow of −$113M.
Last 5 fiscal years
| Fiscal year | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 168 | – |
| Research & development | 83.5 | 108 |
| Operating income | 57.6 | −143 |
| Pre-tax income | 53.4 | −131 |
| Income tax | 1.2 | 0.0 |
| Net income | 52.2 | −131 |
| Diluted EPS | 1.25 | −3.05 |
| Diluted shares | 2.7 | 43.0 |
| Fiscal year | Dec 2024 | Dec 2025 |
|---|---|---|
| Cash & equivalents | 197 | 189 |
| Current assets | 202 | 350 |
| Net PP&E | 6.7 | 5.0 |
| Total assets | 241 | 397 |
| Payables | 1.9 | 1.8 |
| Current liabilities | 20.7 | 22.6 |
| Total liabilities | 43.6 | 42.2 |
| Shareholders' equity | −311 | 355 |
| Fiscal year | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating cash flow | 76.0 | −112 |
| Capital expenditure | 1.1 | 0.8 |
| Free cash flow | 74.8 | −113 |
| Depreciation & amortisation | 3.3 | 2.4 |
| Stock-based compensation | 9.6 | 16.4 |
| Fiscal year | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating income growth (YoY) | – | −348.1% |
| EPS growth (YoY) | – | −344.0% |
| Operating margin | 34.4% | – |
| Net margin | 31.2% | – |
| Return on equityBlank when equity is negative | – | −36.9% |
| ROCEEBIT ÷ (assets − current liabilities) | 26.2% | −38.2% |
| Free cash flow margin | 44.7% | – |
| Cash conversion (CFO ÷ net income) | 1.45x | 0.85x |
| Current ratio | 9.76x | 15.5x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.